Semaglutide for Smoking Cessation: Early Evidence

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

GLP-1 receptor agonists, like semaglutide, are gaining attention for potential uses beyond diabetes and weight loss, with existing anti-amyloid drugs slowing cognitive decline by around 30%.
Research suggests GLP-1s may reduce brain inflammation and protect neurons, opening doors for new applications.
While trials for Alzheimer's disease did not meet primary endpoints, they showed improvement in Alzheimer’s-related biomarkers.
A randomized clinical trial investigated once-weekly semaglutide in adults with alcohol use disorder, and the EVOKE Plus study had 495 locations.

Semaglutide, a medication widely known for treating type 2 diabetes and obesity, is now drawing significant interest for other possible applications, including its potential role in helping people quit smoking. While direct, large-scale studies on semaglutide for smoking cessation are still emerging, early research points to GLP-1 receptor agonists as a potential treatment target for nicotine addiction. This broader interest stems from how GLP-1s affect the brain and nervous system, going beyond their initial metabolic functions. For example, Novo Nordisk released topline results in November 2025 from phase 3 trials for Alzheimer's disease, even though those trials did not meet their primary goals. The ongoing investigation into how these drugs influence addiction pathways, particularly with alcohol use disorder, provides a scientific basis for exploring their utility in smoking cessation.

What are GLP-1 Medications?

GLP-1 medications are a class of drugs known as GLP-1 receptor agonists. These medicines were first developed to help the body manage blood sugar levels, especially in people with type 2 diabetes. They work by mimicking a natural hormone in the body called glucagon-like peptide-1.

Common GLP-1 Drugs You May Know

Many people recognize specific GLP-1 drugs by their brand names. Semaglutide, for instance, is sold as Ozempic®, Wegovy®, and Rybelsus®. Liraglutide is marketed under the names Victoza® and Saxenda®, while tirzepatide is known as Mounjaro® and Zepbound™. Each of these drugs helps regulate blood sugar, and some are also approved for weight management. Their primary role has been in metabolic health, but new research is uncovering other ways they might affect the body.

How They Work for Diabetes and Weight Management

GLP-1 receptor agonists essentially tell the body to release more insulin when blood sugar is high. They also slow down how fast food leaves the stomach, which helps you feel full longer and can lead to eating less. This dual action makes them very effective for managing type 2 diabetes and promoting weight loss. The way these drugs interact with the body’s systems is complex. They don't just act on the pancreas or the stomach. They also have effects on other organs and even the brain, which has opened up new areas of scientific exploration. This broader influence is why researchers are looking into their potential for conditions beyond diabetes and weight.

Beyond Metabolism: New Avenues of Research

The initial success of GLP-1s in diabetes and weight management has prompted scientists to explore their wider impact. We are seeing a shift in thinking about these drugs, moving past their original purposes. Researchers are now actively investigating how GLP-1s might affect the brain, the nervous system, and even conditions like Alzheimer's disease and various forms of addiction. This expansion of research is crucial because it means we are learning more about the full scope of what these medications can do. The findings could potentially reshape how we treat a range of complex health issues, offering new hope for patients. The journey from a diabetes drug to a potential treatment for neurological disorders highlights the dynamic nature of medical science.

How Do GLP-1s Affect the Brain and Addiction?

GLP-1s have effects on the brain and nervous system that extend beyond their known metabolic actions. These drugs may reduce brain inflammation, improve blood vessel health, and even protect neurons. This potential has led to exploring GLP-1s for conditions like Alzheimer's disease and addiction. The Endocrine Society notes that GLP-1s show promise in treating alcohol and drug addiction GLP-1s and addiction. This suggests a broader impact on brain function and behavior.

Impact on Brain Inflammation and Neuron Protection

The brain is a complex organ, and inflammation can play a significant role in various neurological conditions. Research indicates that GLP-1 drugs might help calm this inflammation. By reducing brain inflammation, these medications could protect brain cells, or neurons, from damage. This protective effect is a key reason why scientists are excited about GLP-1s for conditions that involve brain health. Improved blood vessel health in the brain is another benefit. Healthy blood vessels ensure that brain cells get enough oxygen and nutrients, which is vital for their proper function. The idea that a drug designed for diabetes could offer such neuroprotective benefits is a significant development in medical research. These findings open the door to new ways of understanding and treating brain-related disorders.

GLP-1s and the Brain's Reward System

One of the most intriguing aspects of GLP-1s is their potential influence on the brain's reward system. This system is a network of brain structures that controls our responses to pleasurable activities, including eating, drinking, and even drug use. When we experience something rewarding, this system releases dopamine, a neurotransmitter that makes us feel good. Addictive behaviors, whether related to food, alcohol, or nicotine, often involve an overactive or dysregulated reward system. Scientists are investigating whether GLP-1s can modulate this system. For instance, by affecting hunger and satiety signals, GLP-1s might reduce the rewarding feelings associated with certain foods. This mechanism could also apply to other rewarding substances, such as alcohol or nicotine. If GLP-1s can dampen the "reward" signals associated with addictive substances, they could help reduce cravings and compulsive behaviors.

Evidence for Addiction Treatment

The promise of GLP-1s in treating addiction is growing. While the primary focus has been on alcohol use disorder, the underlying mechanisms could extend to other forms of addiction. The Endocrine Society has highlighted the potential of GLP-1s in this area, pointing to their ability to affect brain pathways involved in addiction. This research suggests that GLP-1s might offer a new therapeutic approach for individuals struggling with substance use. The idea is that by altering brain chemistry in specific ways, these drugs could make addictive substances less appealing or reduce the intense cravings that drive addiction. This is a significant area of ongoing research, and the initial findings are encouraging for developing new treatments for a range of addictive behaviors.

What Does the Science Say About Semaglutide and Alcohol Use?

The science suggests that GLP-1s, including semaglutide, may have a role in treating alcohol use disorder. A randomized clinical trial investigated once-weekly semaglutide in adults with alcohol use disorder GLP-1s and alcohol use disorder. This study looked at how semaglutide affected alcohol consumption and other related outcomes.

Findings from Clinical Trials on Alcohol Use

The randomized clinical trial focused on adults diagnosed with alcohol use disorder. Researchers wanted to see if semaglutide could help reduce the amount of alcohol these individuals consumed. The study measured several key indicators. One was laboratory self-administration of alcohol, which was quantified in estimated grams of alcohol. This allowed researchers to objectively assess how much alcohol participants chose to drink in a controlled setting. Another important measure was peak breath alcohol concentration (BrAC). This provides a direct measure of alcohol in the bloodstream after consumption. The trial also tracked prospective changes in weekly alcohol outcomes, looking at trends over time.

For instance, Figure 2 in the study details laboratory self-administration, showing estimated grams of alcohol and peak measured BrAC. It depicts posttreatment alcohol self-administration following treatment week 8, specifically for the 0.5 mg/wk dose, while controlling for pretreatment self-administration among those with complete data (n = 25; 12 in the placebo group and 13 in the semaglutide group). Figure 3 further illustrates prospective changes in weekly alcohol outcomes. These detailed measurements provide concrete data on semaglutide's potential impact on drinking behaviors.

Protecting the Liver During Alcohol Consumption

Beyond reducing alcohol intake, GLP-1 receptor agonists may offer another important benefit for individuals who consume alcohol. According to Yale School of Medicine, these medications may protect the liver during alcohol consumption GLP-1s protect liver from alcohol. Alcohol can be very damaging to the liver, leading to conditions like fatty liver disease, alcoholic hepatitis, and cirrhosis. The potential for GLP-1s to offer a protective effect is significant. This means that even if a person continues to consume some alcohol, GLP-1s might help mitigate some of the harmful effects on the liver. This liver-protective mechanism adds another layer of therapeutic potential for these drugs in the context of alcohol use disorder.

Mechanisms Behind Reduced Alcohol Cravings

The exact ways GLP-1s reduce alcohol cravings are still being investigated, but several mechanisms are proposed. One theory involves the brain's reward system, as discussed earlier. By modulating dopamine pathways, GLP-1s might make alcohol less rewarding, thereby reducing the desire to drink. Another mechanism could be related to appetite regulation. GLP-1s are known to affect hunger and satiety signals. Some research suggests that cravings for addictive substances can be linked to dysregulated energy balance or reward pathways that are also involved in eating behaviors. By normalizing these pathways, GLP-1s could indirectly reduce cravings for alcohol. The complexity of addiction means that multiple brain systems are involved, and GLP-1s appear to influence several of them. The promising results from trials investigating semaglutide in adults with alcohol use disorder highlight the need for further research into these mechanisms.

Is There Evidence for Semaglutide in Smoking Cessation?

While direct, large-scale studies on semaglutide specifically for smoking cessation are still emerging, the overlap with addiction research is notable. The potential impact of GLP-1s on reward pathways and brain function, seen in alcohol studies, suggests a possible role in other substance use disorders. Early evidence points to GLP-1 receptor agonists as a potential treatment target for nicotine addiction GLP-1s and nicotine addiction. Another study from 2024 explored GLP-1 receptor agonists for drug addiction GLP-1s for drug addiction.

The Link Between Alcohol and Nicotine Addiction

Alcohol and nicotine addiction share common pathways in the brain's reward system. Both substances activate dopamine release, leading to pleasurable feelings and reinforcing the addictive behavior. This shared neurobiology is why treatments that work for one addiction might also be effective for another. The research showing GLP-1s' potential in alcohol use disorder provides a strong basis for exploring their use in smoking cessation. If semaglutide can reduce alcohol cravings by modulating the reward system, it might also be able to reduce nicotine cravings through similar mechanisms. This cross-addiction potential is a significant area of scientific inquiry. Understanding these shared pathways is key to developing broader treatments for substance use disorders.

Early Research and Animal Studies

Initial investigations into GLP-1s and nicotine addiction often start with animal studies. These studies can help researchers understand the fundamental biological mechanisms at play. For example, some early evidence suggests that GLP-1 receptor agonists could modulate the brain circuits involved in nicotine reward and withdrawal. This means the drugs might make smoking less pleasurable or reduce the unpleasant symptoms associated with quitting. While animal studies are not directly transferable to humans, they provide crucial insights and guide future human clinical trials. The fact that GLP-1 receptor agonists are being identified as a "potential treatment target" for nicotine addiction indicates that scientists are actively pursuing this line of research. The 2024 study on GLP-1 receptor agonists for drug addiction further supports the idea that these drugs have broad anti-addictive properties.

Future Directions for Smoking Cessation Trials

Given the promising results in alcohol addiction and the shared brain pathways with nicotine addiction, it is highly likely that more human clinical trials will be conducted to specifically investigate semaglutide's effectiveness for smoking cessation. These trials would need to be well-designed, randomized, and placebo-controlled, similar to the alcohol use disorder study. They would measure outcomes such as the number of cigarettes smoked per day, the duration of abstinence, and the intensity of cravings. If successful, semaglutide could offer a new option for individuals struggling to quit smoking, especially those who have not found success with existing therapies. The ongoing research into GLP-1s for various forms of addiction highlights a growing recognition of their versatile therapeutic potential.

What About Semaglutide and Alzheimer's Disease?

Semaglutide has gained attention for its potential to help treat Alzheimer's disease, as noted by the Alzheimer's Association GLP-1s and Alzheimer's disease. This possibility generated considerable excitement, leading to significant clinical trials.

The EVOKE and EVOKE+ Trials

Two global clinical trials, named EVOKE and EVOKE+, studied semaglutide in individuals with early-stage Alzheimer’s disease. These trials aimed to investigate whether semaglutide could slow the progression of cognitive decline in these patients. The EVOKE Plus study, for instance, was a massive undertaking, involving 495 locations across the United States and globally. In the U.S., locations included cities like Phoenix, Scottsdale, and Sun City in Arizona, as well as Anaheim, Lomita, and Long Beach in California EVOKE Plus study details. The scale of these trials shows the significant hope placed on GLP-1s for Alzheimer's treatment.

Trial Results and Primary Endpoints

In November 2025, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials. The outcome was that the trials did not meet their primary endpoints. This means semaglutide did not show a statistically significant improvement in cognitive function as the main goal of the study. This news was disappointing for many in the Alzheimer's research community. However, the completion of these trials still marks a critical moment in Alzheimer’s research, as they evaluated a mechanism grounded in the biology of aging, expanding beyond the traditional focus on amyloid.

"While it is disappointing that the trials did not meet their primary endpoints, they show a fundamental shift in how we approach the development of new Alzheimer’s treatments, expanding beyond amyloid to target the complete pathobiology of the disease," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF) Semaglutide in Alzheimer's trials. This perspective highlights that even without hitting the primary goal, the trials contributed valuable knowledge.

Biomarker Improvements and Future Potential

Despite not meeting the primary endpoints related to cognitive decline, Novo Nordisk did note an improvement of Alzheimer’s-related biomarkers in both trials. Biomarkers are measurable indicators of a biological state or condition. These improvements suggest that semaglutide might still have some positive effects on the underlying biology of Alzheimer's disease, even if those effects didn't translate into significant cognitive benefits in these specific trials.

Dr. Fillit further explained, "Novo has noted an improvement of Alzheimer’s-related biomarkers in both trials. We look forward to seeing further results at CTAD, as this may suggest a path forward for semaglutide as part of a combination therapy approach. Existing anti-amyloid drugs slow cognitive decline by around 30%, so therapies aimed at other pathways will be crucial as we chip away at the remaining 70%." This means semaglutide could potentially be used alongside other treatments to achieve a more comprehensive effect. Current anti-amyloid drugs slow cognitive decline by approximately 30%, indicating a large gap that other therapies need to address. The exploration of GLP-1s, even with mixed results, pushes the field forward in understanding the disease's complexity.

What's Next for GLP-1 Research in Addiction and Other Conditions?

The future of GLP-1 research in addiction and other conditions remains promising, despite some recent setbacks in specific trials. Even though the Alzheimer's trials did not meet their primary endpoints, the observed improvements in Alzheimer’s-related biomarkers suggest a continued path forward for semaglutide, potentially as part of a combination therapy approach. This reflects a broader shift in how researchers are thinking about complex diseases.

The Shift Towards Combination Therapies

The concept of combination therapy is gaining significant traction in treating complex diseases like Alzheimer's and various addictions. Just as cancer care has been transformed by using multiple drugs that target different pathways, the same approach is being considered for neurological disorders. Howard Fillit, MD, emphasized this point, stating that the completion of two phase 3 trials targeting non-amyloid pathways "represents real momentum toward the kind of combination approach that has already transformed cancer care." This means that even if one drug doesn't fully solve the problem on its own, it might be a crucial piece of a larger treatment puzzle.

Existing anti-amyloid drugs, for example, slow cognitive decline by around 30%. This leaves a substantial 70% of the decline that still needs to be addressed. Therapies that target other pathways, like GLP-1s, are crucial for "chipping away" at this remaining percentage. Therefore, the next steps for semaglutide in Alzheimer's research might involve testing it in combination with other drugs, rather than as a standalone treatment. This strategy acknowledges the multifaceted nature of the disease and seeks to tackle it from several angles simultaneously.

Continued Exploration in Addiction and Neurological Health

Research continues to explore the broader applications of GLP-1s in conditions involving neurological and addictive behaviors. The promising results from studies on alcohol use disorder provide a strong foundation for further investigation into other addictions, including nicotine. The understanding that GLP-1s can influence brain inflammation, neuronal protection, and the reward system opens up a wide array of possibilities. Scientists are actively looking into how these drugs might help regulate cravings, reduce relapse rates, and improve overall brain health in individuals with various substance use disorders.

Beyond addiction, the neuroprotective properties of GLP-1s are still a subject of intense study. Researchers are examining their potential role in other neurodegenerative conditions, even if the initial Alzheimer's trials had mixed results. The focus is on understanding the specific biological effects of GLP-1s on the brain and how these effects can be harnessed therapeutically. This ongoing exploration ensures that the full potential of this class of medications is thoroughly investigated, potentially leading to breakthroughs in areas we are only just beginning to understand. The journey of GLP-1s from diabetes management to a potential tool in neurological and addiction medicine is a testament to the continuous evolution of scientific discovery.

Frequently Asked Questions

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are a class of medications designed primarily to help the body regulate blood sugar levels. They mimic a natural hormone called glucagon-like peptide-1. Common examples include semaglutide (Ozempic®, Wegovy®, Rybelsus®), liraglutide (Victoza®, Saxenda®), and tirzepatide (Mounjaro®, Zepbound™). These drugs are widely used for treating type 2 diabetes and obesity.

Has semaglutide been approved for smoking cessation?

No, semaglutide has not been approved specifically for smoking cessation. While there is early research suggesting GLP-1 receptor agonists could be a potential treatment target for nicotine addiction, large-scale clinical trials for this specific use are still emerging. Most of the current evidence related to addiction comes from studies on alcohol use disorder.

How do GLP-1s affect the brain?

GLP-1s may have significant effects on the brain and nervous system. Research suggests these drugs can reduce brain inflammation, improve the health of blood vessels in the brain, and protect neurons from damage. These neuroprotective effects are a key reason why GLP-1s are being explored for conditions like Alzheimer's disease and various forms of addiction.

What were the results of semaglutide trials for Alzheimer's disease?

In November 2025, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials for early-stage Alzheimer's disease. The trials did not meet their primary endpoints, meaning semaglutide did not show a statistically significant improvement in cognitive function as the main goal. However, Novo Nordisk did note an improvement in Alzheimer’s-related biomarkers in both trials, suggesting potential for future combination therapies.

Can GLP-1s help with other addictions besides alcohol?

Yes, research suggests GLP-1s may show promise in treating other forms of addiction beyond alcohol. The Endocrine Society has indicated that GLP-1s show promise in treating both alcohol and drug addiction. This is likely due to their influence on the brain's reward pathways and ability to modulate cravings, which are common mechanisms across different substance use disorders.